文献速递心力衰竭与心肌病

国家生物样本库中肥厚型心肌病风险的罕见与常见遗传变异

Rare and Common Genetic Variation Underlying the Risk of Hypertrophic Cardiomyopathy in a National Biobank.
PubMed 文献 · JAMA Cardiol · 2022-01-01

结果显示ACMG核心基因致病/可能致病变异与HCM风险升高55倍相关,多基因评分每升高1个标准差OR为1.6,联合遗传因素使临床风险预测的AUC从0.71提升至0.82。

要点

  • ACMG 14个核心基因致病/可能致病变异与HCM风险升高55倍相关。
  • 多基因评分每升高1个标准差,HCM风险OR为1.6。
  • 在临床因素基础上加入遗传因素,AUC从0.71升至0.82。

核心结论

  • 罕见与常见遗传变异均显著贡献于一般人群HCM易感性。
  • 遗传因素可改善超越临床因素的HCM风险预测。

研究设计与样本

  • 基于英国生物样本库(2006-2010)与Mass General Brigham生物样本库(2010-2019)的队列研究。

主要发现

  • 14个ACMG核心基因致病/可能致病变异与HCM风险升高55倍相关(95%CI 35-83)。
  • 非ACMG的37个基因变异与HCM无显著关联(OR 1.8,95%CI 0.6-4.0)。
  • MYBPC3(OR 72,95%CI 39-124)、MYH7(OR 61,95%CI 26-121)和ALPK3功能丧失变异(OR 13,95%CI 4.4-28)与HCM强相关。
  • 多基因评分每升高1个标准差,HCM风险OR为1.6(95%CI 1.4-1.8),Mass General Brigham生物样本库结果一致。

关键数值与推荐

  • ACMG核心基因致病/可能致病变异与HCM风险升高55倍相关(95%CI 35-83)。
  • 多基因评分每升高1个标准差OR为1.6(95%CI 1.4-1.8)。
  • 在临床风险因素(肥胖、高血压、房颤、冠心病)基础上加入罕见变异携带状态和多基因评分,AUC从0.71(95%CI 0.65-0.77)提升至0.82(95%CI 0.77-0.87)。

临床怎么用

  • 临床可结合罕见变异携带状态与多基因评分,提升HCM风险预测。
  • ACMG核心基因变异应纳入HCM遗传风险评估,非ACMG基因变异证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death in young people. Although rare genetic variants are well-established contributors to HCM risk, common genetic variants have recently been implicated in disease pathogenesis. OBJECTIVE: To assess the contributions of rare and common genetic variation to risk of HCM in the general population. DESIGN, SETTING, AND PARTICIPANTS: This cohort study of the UK Biobank (data from 2006-2010) and the Mass General Brigham Biobank (2010-2019) assessed the relative and joint contributions of rare genetic variants and a common variant (polygenic) score to risk of HCM. Both rare and common variant predictors were then evaluated in the context of relevant clinical risk factors. Data analysis was conducted from May 2021 to February 2022. EXPOSURES: Pathogenic rare variants, common-variant (polygenic) score, and clinical risk factors. MAIN OUTCOMES AND MEASURES: Risk of HCM. RESULTS: The primary study population comprised 184 511 individuals from the UK Biobank. Mean (SD) age was 56 (8) years, 83 690 (45%) of participants were men, and 204 (0.1%) participants had HCM. Of 51 genes included in clinical genetic testing panels for HCM, pathogenic or likely pathogenic variants in 14 core genes (designated by the American College of Medical Genetics and Genomics [ACMG]) were associated with 55-fold higher odds (95% CI, 35-83) of HCM, while those in the remaining 37 non-ACMG genes were not significantly associated with HCM (OR, 1.8; 95% CI, 0.6-4.0). ClinVar pathogenic or likely pathogenic mutations in MYBPC3 (OR, 72; 95% CI, 39-124) and MYH7 (OR, 61; 95% CI, 26-121) were strongly associated with HCM, as were loss-of-function variants in ALPK3 (OR, 13; 95% CI, 4.4-28). A polygenic score was strongly associated with HCM (OR per SD increase in score, 1.6; 95% CI, 1.4-1.8), with concordant results in the Mass General Brigham Biobank. Genetic factors enhanced clinical risk prediction for HCM: addition of rare variant carrier status and the polygenic score to clinical risk factors (obesity, hypertension, atrial fibrillation, and coronary artery disease) improved the area under the receiver operator characteristic curve from 0.71 (95% CI, 0.65-0.77) to 0.82 (95% CI, 0.77-0.87). CONCLUSIONS AND RELEVANCE: Both rare and common genetic variants contribute substantially to HCM susceptibility in the general population and improve HCM risk prediction beyond that achieved with clinical factors.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Biddinger KJ, Jurgens SJ, Maamari D, et al. Rare and Common Genetic Variation Underlying the Risk of Hypertrophic Cardiomyopathy in a National Biobank. JAMA Cardiol. 2022. PMID: 35583889. doi:10.1001/jamacardio.2022.1061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。